The Administration Core will provide executive oversight and administrative support for all of the projects and cores that comprise the Leukemia SPORE. The goal of the Administration Core is to monitor the activities of all of the program components, to comply with all local and federal guideline for grant administration, and to facilitate communication and collaboration among the program members. Accordingly, the specific aims of the Administration Core are as follows:
Aim 1. To facilitate intra- and inter-SPORE communication and collaboration. We will organize monthly SPORE meetings and the development and maintenance of a Leukemia SPORE web site.
Aim 2. To provide administrative and fiscal oversight and support for all SPORE components. This core will be responsible for interacting with the Grants and Contracts Office at Washington University and with staff at the NCI, including preparation and submission of annual progress reports.
Aim 3. To coordinate all SPORE-related meetings. This core will coordinate the meetings of the External Advisory Board, attendance at the annual SPORE workshop, and monthly meetings of the Leukemia SPORE Steering Committee.
Aim 4. To coordinate administrative activities of the SPORE Developmental Research Program. This core will solicit applications for pilot projects and coordinate the review of these applications.
Aim 5. To coordinate the SPORE Career Development Program. This core will assist in the recruitment and monitoring of candidates in this program.
Aim 6. To assist investigators with the preparation of scholarly presentations, publications, regulatory documents, and all other SPORE-related paperwork.
Aim 7. To enhance participation of minorities in SPORE activities.
Aim 8. To ensure advocacy issues are addressed and included in all aspects fo research with patient participants.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA171963-02
Application #
8764905
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
2014-07-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$103,097
Indirect Cost
$51,269
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521
Jacoby, Meagan A; Duncavage, Eric J; Chang, Gue Su et al. (2018) Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight 3:
Monlish, Darlene A; Bhatt, Sima T; Duncavage, Eric J et al. (2018) Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS. Blood 131:1032-1035
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494
Staser, Karl W; Eades, William; Choi, Jaebok et al. (2018) OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood. Cytometry A 93:186-189
Warner, Wayne A; Spencer, David H; Trissal, Maria et al. (2018) Expression profiling of snoRNAs in normal hematopoiesis and AML. Blood Adv 2:151-163
Nguyen, Hai Dang; Leong, Wan Yee; Li, Weiling et al. (2018) Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. Cancer Res 78:5363-5374
Cooper, Matthew L; Choi, Jaebok; Staser, Karl et al. (2018) An ""off-the-shelf"" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 32:1970-1983
Wang, Tianjiao; Jacoby, Meagan A; Duncavage, Eric J et al. (2018) Exome analysis of treatment-related AML after APL suggests secondary evolution. Br J Haematol :
Bansal, Dhruv; Vij, Kiran; Chang, Gue Su et al. (2018) Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. Haematologica 103:e270-e273

Showing the most recent 10 out of 64 publications